You just read:

Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties

News provided by

Immunomedics, Inc.

Feb 10, 2017, 06:50 ET